Karyopharm Therapeutics (KPTI) EBITDA (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported EBITDA for 15 consecutive years, with -$22.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 7.63% year-over-year to -$22.5 million; the trailing twelve-month figure through Jun 2026 stood at -$80.0 million (up 30.58% YoY), and the FY2025 full-year result was -$90.7 million, up 24.06% from the prior year.
• EBITDA eased to -$22.5 million in Q2 2026 per KPTI's latest filing, from -$17.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$15.2 million in Q3 2025 and bottomed at -$42.9 million in Q2 2022.
• Historically, EBITDA has averaged -$29.7 million across 5 years, with a median of -$30.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA sank 172.12% in 2022, then jumped 42.96% in 2025.
• Over 5 years, EBITDA stood at -$33.9 million in 2022, then fell by 11.63% to -$37.8 million in 2023, then gained by 17.26% to -$31.3 million in 2024, then surged by 42.96% to -$17.8 million in 2025, then fell by 26.24% to -$22.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$22.5 million, -$17.8 million, and -$15.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.